A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results

This phase III trial compared adjuvant whole-brain radiotherapy (WBRT) with observation after either surgery or radiosurgery of a limited number of brain metastases in patients with stable solid tumors. Here, we report the health-related quality-of-life (HRQOL) results. HRQOL was a secondary end poi...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of clinical oncology Ročník 31; číslo 1; s. 65
Hlavní autori: Soffietti, Riccardo, Kocher, Martin, Abacioglu, Ufuk M, Villa, Salvador, Fauchon, François, Baumert, Brigitta G, Fariselli, Laura, Tzuk-Shina, Tzahala, Kortmann, Rolf-Dieter, Carrie, Christian, Ben Hassel, Mohamed, Kouri, Mauri, Valeinis, Egils, van den Berge, Dirk, Mueller, Rolf-Peter, Tridello, Gloria, Collette, Laurence, Bottomley, Andrew
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 01.01.2013
Predmet:
Brain Neoplasms - radiotherapy
Brain Neoplasms - secondary
Cranial Irradiation
Europe
Follow-Up Studies
Health Status
Humans
International Agencies
Neoplasm Staging
Neoplasms - complications
Neoplasms - pathology
Neoplasms - surgery
Patient Compliance
Postoperative Complications
Prognosis
Quality of Life
Radiosurgery - adverse effects
Radiotherapy, Adjuvant
Survival Rate
Europe
ISSN:1527-7755, 1527-7755
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:This phase III trial compared adjuvant whole-brain radiotherapy (WBRT) with observation after either surgery or radiosurgery of a limited number of brain metastases in patients with stable solid tumors. Here, we report the health-related quality-of-life (HRQOL) results. HRQOL was a secondary end point in the trial. HRQOL was assessed at baseline, at 8 weeks, and then every 3 months for 3 years with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 and Brain Cancer Module. The following six primary HRQOL scales were considered: global health status; physical, cognitive, role, and emotional functioning; and fatigue. Statistical significance required P ≤ .05, and clinical relevance required a ≥ 10-point difference. Compliance was 88.3% at baseline and dropped to 45.0% at 1 year; thus, only the first year was analyzed. Overall, patients in the observation only arm reported better HRQOL scores than did patients who received WBRT. The differences were statistically significant and clinically relevant mostly during the early follow-up period (for global health status at 9 months, physical functioning at 8 weeks, cognitive functioning at 12 months, and fatigue at 8 weeks). Exploratory analysis of all other HRQOL scales suggested worse scores for the WBRT group, but none was clinically relevant. This study shows that adjuvant WBRT after surgery or radiosurgery of a limited number of brain metastases from solid tumors may negatively impact some aspects of HRQOL, even if these effects are transitory. Consequently, observation with close monitoring with magnetic resonance imaging (as done in the EORTC trial) is not detrimental for HRQOL.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1527-7755
1527-7755
DOI:10.1200/JCO.2011.41.0639